Sciclone Pharmaceuticals (SCLN) Files $100M Mixed Shelf; 10M Common for Shareholders
Tweet
Share
E-mailGet Alerts SCLN Hot Sheet
Join SI Premium – FREE
Sciclone Pharmaceuticals, Inc. (Nasdaq: SCLN) filed a registration with the U.S. Securities and Exchange Commission to sell, from time to time, up to $100 million of Common Stock, Preferred Stock, Debt Securities, Warrants to Purchase Common Stock, Preferred Stock, Debt Securities, Units, or any combination thereof.
The company also filed to sell up to 10 million Shares of Common Stock Offered by Selling Stockholders. Sciclone Pharmaceuticals will not receive proceeds from the secondary offering.
The company also filed to sell up to 10 million Shares of Common Stock Offered by Selling Stockholders. Sciclone Pharmaceuticals will not receive proceeds from the secondary offering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Singularity Future Technology closes $5M registered direct offering
- Silexion Therapeutics faces Nasdaq delisting over equity shortfall
- ESS Tech closes $3.2M stock offering at $0.50 per share
Create E-mail Alert Related Categories
Equity OfferingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
